Xun Lin

4.9k total citations · 1 hit paper
94 papers, 2.2k citations indexed

About

Xun Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Xun Lin has authored 94 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pulmonary and Respiratory Medicine, 47 papers in Oncology and 33 papers in Cancer Research. Recurrent topics in Xun Lin's work include Renal cell carcinoma treatment (40 papers), Prostate Cancer Treatment and Research (28 papers) and PARP inhibition in cancer therapy (22 papers). Xun Lin is often cited by papers focused on Renal cell carcinoma treatment (40 papers), Prostate Cancer Treatment and Research (28 papers) and PARP inhibition in cancer therapy (22 papers). Xun Lin collaborates with scholars based in United States, France and Italy. Xun Lin's co-authors include Ronit Simantov, Toni K. Choueiri, Rana R. McKay, Robert J. Motzer, Ewa Matczak, Brian I. Rini, Neal D. Shore, Karim Fizazi, María José Lechuga and Bernard Escudier and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Xun Lin

91 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020 266 citations Cora N. Sternberg, Karim Fizazi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xun Lin United States	23	1.4k	943	823	617	280	94	2.2k
Carol Peña France	7	875 0.6×	765 0.8×	910 1.1×	492 0.8×	92 0.3×	9	2.3k
Sibyl Anderson United States	19	1.2k 0.9×	695 0.7×	944 1.1×	524 0.8×	124 0.4×	40	2.1k
Vinod Ganju Australia	24	906 0.6×	2.0k 2.1×	655 0.8×	447 0.7×	445 1.6×	94	2.7k
D. Mavroudis Greece	29	1.0k 0.7×	2.1k 2.3×	543 0.7×	931 1.5×	240 0.9×	87	2.7k
G. Robinet France	23	2.3k 1.6×	2.1k 2.2×	522 0.6×	325 0.5×	240 0.9×	110	3.0k
N. Moore Switzerland	16	2.6k 1.8×	2.0k 2.1×	1.7k 2.1×	1.2k 2.0×	173 0.6×	27	4.0k
Taral Patel United States	14	1.1k 0.8×	1.4k 1.4×	476 0.6×	263 0.4×	405 1.4×	38	2.1k
Lorenza Landi Italy	22	1.0k 0.7×	1.1k 1.2×	611 0.7×	423 0.7×	96 0.3×	85	1.8k
Jamal Tarazi United States	24	2.0k 1.4×	1.0k 1.1×	1.4k 1.7×	960 1.6×	84 0.3×	65	2.6k
Vera Gorbounova Russia	13	1.8k 1.3×	2.2k 2.4×	617 0.7×	354 0.6×	156 0.6×	23	3.2k

Countries citing papers authored by Xun Lin

Since Specialization

Citations

This map shows the geographic impact of Xun Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xun Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xun Lin more than expected).

Fields of papers citing papers by Xun Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xun Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xun Lin. The network helps show where Xun Lin may publish in the future.

Co-authorship network of co-authors of Xun Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Xun Lin. A scholar is included among the top collaborators of Xun Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xun Lin. Xun Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2025). Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.. Journal of Clinical Oncology. 43(5_suppl). 11 indexed citations

Azad, Arun, Karim Fizazi, Douglas Laird, et al.. (2024). Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5020–5020.

Azad, Arun, André P. Fay, Cezary Szczylik, et al.. (2024). 1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study. Annals of Oncology. 35. S987–S988. 1 indexed citations

Matsubara, Nobuaki, Karim Fizazi, Arun Azad, et al.. (2023). 1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status. Annals of Oncology. 34. S977–S978. 3 indexed citations

Shaya, Justin, et al.. (2021). Prognostic Significance of Pancreatic Metastases in Patients With Advanced Renal Cell Carcinoma Treated With Systemic Therapy. Clinical Genitourinary Cancer. 19(6). e367–e373. 4 indexed citations

Giorgi, Ugo De, Maha Hussain, Neal D. Shore, et al.. (2021). Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer. 159. 237–246. 8 indexed citations

Lin, Xun, et al.. (2020). The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer. 18(5). e598–e609. 9 indexed citations

Rini, Brian I., Bernard Escudier, Jean-François Martini, et al.. (2018). Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. Clinical Cancer Research. 24(18). 4407–4415. 45 indexed citations

Staehler, Michael, Robert J. Motzer, Daniel J. George, et al.. (2018). Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Annals of Oncology. 29(10). 2098–2104. 32 indexed citations

10.

Velasco, Guillermo de, Xun Lin, Craig Norton, et al.. (2017). The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. Clinical Genitourinary Cancer. 16(2). e327–e333. 13 indexed citations

11.

Lalani, Aly‐Khan A., Rana R. McKay, Xun Lin, et al.. (2017). Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 15(6). 724–732. 38 indexed citations

12.

Tannir, Nizar M., Robert A. Figlin, Martin Gore, et al.. (2017). Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clinical Genitourinary Cancer. 16(1). 6–12.e4. 13 indexed citations

13.

Ravaud, Alain, Robert J. Motzer, Hardev Pandha, et al.. (2016). genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). Annals of Oncology. 27. vi565–vi565. 1 indexed citations

14.

McKay, Rana R., Xun Lin, Laurence Albigès, et al.. (2015). Statins and survival outcomes in patients with metastatic renal cell carcinoma. European Journal of Cancer. 52. 155–162. 40 indexed citations

15.

Hutson, Thomas E., Ronald M. Bukowski, Brian I. Rini, et al.. (2014). Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. British Journal of Cancer. 110(5). 1125–1132. 57 indexed citations

16.

Molina, Ana M., Xun Lin, Beata Korytowsky, et al.. (2013). Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. European Journal of Cancer. 50(2). 351–358. 111 indexed citations

17.

Motzer, Robert J., Bernard Escudier, Ronald M. Bukowski, et al.. (2013). Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. British Journal of Cancer. 108(12). 2470–2477. 108 indexed citations

18.

Oh, Do‐Youn, Reza Khosravan, Xun Lin, et al.. (2013). Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Investigational New Drugs. 31(6). 1547–1558. 20 indexed citations

19.

Cutsem, Eric Van, Feng Gao, James A. Williams, et al.. (2011). ASSOCIATIONS BETWEEN GERMLINE GENOTYPE AND EFFICACY AND SAFETY OUTCOMES IN A PHASE III STUDY OF SUNITINIB AND FOLFIRI IN METASTATIC COLORECTAL CANCER (MCRC). Annals of Oncology. 22. 1 indexed citations

20.

Lin, Xun & Qiang Xu. (2009). A new method for the comparison of survival distributions. Pharmaceutical Statistics. 9(1). 67–76. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact